Abstract
High dose busulfan (BU) has become a mainstay in conditioning regimens for hematopoietic stem cell transplantation (HSCT), despite its unpredictable response, narrow therapeutic index and severe toxicity. The present study provides an integration of pharmacokinetic and genetic data of 63 adults with acute myeloid leukemia (AML) preconditioned for HSCT with high dose oral BU, with the aim of defining biomarkers predictive of poor BU metabolism.
BU area under the concentration time curve (AUC) demonstrated that 76% of the patients achieved target AUC; 24% required dose modification. The main findings of this study were: (1) AML patients carrying the GSTP1 rs1695 variant allele were at risk of developing supra-therapeutic BU-AUC due to reduced BU clearance. (2) Combined polymorphisms in GSTM1 and ABCB1 were associated with BU clearance and AUC rates. In conclusion, GST and ABCB1 genotyping may assist care-givers in personalizing BU dosage with less trial-and-error and may enable preemptive identification of patients at risk for BU toxicity.Keywords: Busulfan, HSCT, pharmacokinetics, pharmacogenetics, SNP, toxicity, GST, ABCB1
Current Drug Safety
Title:Pharmacokinetic and Pharmacogenetic Analysis of Oral Busulfan in Stem Cell Transplantation: Prediction of Poor Drug Metabolism to Prevent Drug Toxicity
Volume: 7 Issue: 3
Author(s): Norberto Krivoy, Tsila Zuckerman, Hela Elkin, Lia Froymovich, Jacob M. Rowe and Edna Efrati
Affiliation:
Keywords: Busulfan, HSCT, pharmacokinetics, pharmacogenetics, SNP, toxicity, GST, ABCB1
Abstract: High dose busulfan (BU) has become a mainstay in conditioning regimens for hematopoietic stem cell transplantation (HSCT), despite its unpredictable response, narrow therapeutic index and severe toxicity. The present study provides an integration of pharmacokinetic and genetic data of 63 adults with acute myeloid leukemia (AML) preconditioned for HSCT with high dose oral BU, with the aim of defining biomarkers predictive of poor BU metabolism.
BU area under the concentration time curve (AUC) demonstrated that 76% of the patients achieved target AUC; 24% required dose modification. The main findings of this study were: (1) AML patients carrying the GSTP1 rs1695 variant allele were at risk of developing supra-therapeutic BU-AUC due to reduced BU clearance. (2) Combined polymorphisms in GSTM1 and ABCB1 were associated with BU clearance and AUC rates. In conclusion, GST and ABCB1 genotyping may assist care-givers in personalizing BU dosage with less trial-and-error and may enable preemptive identification of patients at risk for BU toxicity.Export Options
About this article
Cite this article as:
Krivoy Norberto, Zuckerman Tsila, Elkin Hela, Froymovich Lia, M. Rowe Jacob and Efrati Edna, Pharmacokinetic and Pharmacogenetic Analysis of Oral Busulfan in Stem Cell Transplantation: Prediction of Poor Drug Metabolism to Prevent Drug Toxicity, Current Drug Safety 2012; 7 (3) . https://dx.doi.org/10.2174/157488612803251324
DOI https://dx.doi.org/10.2174/157488612803251324 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis
Current Vascular Pharmacology Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology Advances in Drug Safety
Current Pharmaceutical Design Cutoff Values of D-Dimer and FDP in Plasma for the Diagnosis of Thrombosis
Vascular Disease Prevention (Discontinued) HPMC- A Marvel Polymer for Pharmaceutical Industry-Patent Review
Recent Advances in Drug Delivery and Formulation Fast Food Versus Slow Food and Hypertension Control
Current Hypertension Reviews Aging and DNA Methylation
Current Chemical Biology The Bovine Basic Pancreatic Trypsin Inhibitor (Kunitz Inhibitor): A Milestone Protein
Current Protein & Peptide Science Thrombophilia and Pregnancy
Current Pharmaceutical Design An Update on Management of Acute and Chronic Open Wounds: The Importance of Moist Environment in Optimal Wound Healing
Medicinal Chemistry Reviews - Online (Discontinued) Mechanisms of Inflammatory Atherosclerosis in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) Relevance of Postprandial Lipemia in Metabolic Syndrome
Current Vascular Pharmacology Toxins of Animal Venoms and Inhibitors: Molecular and Biotechnological Tools Useful to Human and Animal Health
Current Topics in Medicinal Chemistry The Role of Coagulation and Fibrinolysis in the Pathogenesis of Acute Lung Injury
Current Respiratory Medicine Reviews Novel Risk Factors Related to Stable Angina
Current Pharmaceutical Design Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism
Current Drug Targets Patent Selections
Recent Patents on Nanomedicine Recent Developments in Bioactive Ceramic/Glass: Preparation and Application in Tissue Engineering and Drug Delivery
Recent Patents on Materials Science Bladder Injury During Cesarean Delivery
Current Women`s Health Reviews